Compare · IOBT vs NVO
IOBT vs NVO
Side-by-side comparison of IO Biotech Inc. (IOBT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IOBT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.77B, about 877.7x IOBT ($224.2M).
- Over the past year, IOBT is down 96.9% and NVO is down 41.1% - NVO leads by 55.8 points.
- NVO has hit the wire 11 times in the past 4 weeks while IOBT has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 7 for IOBT).
- Company
- IO Biotech Inc.
- Novo Nordisk A/S
- Price
- $0.05+54.32%
- $42.91-2.60%
- Market cap
- $224.2M
- $196.77B
- 1M return
- -84.88%
- -2.21%
- 1Y return
- -96.90%
- -41.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 11
- Recent ratings
- 7
- 25
IO Biotech Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IOBT
- Amendment: SEC Form SCHEDULE 13G/A filed by IO Biotech Inc.
- IO Biotech Inc. filed SEC Form 8-K: Bankruptcy or Receivership
- SEC Form 8-K filed by IO Biotech Inc.
- SEC Form SCHEDULE 13G filed by IO Biotech Inc.
- SEC Form 8-K filed by IO Biotech Inc.
- IO Biotech Provides Corporate Update
- IO Biotech downgraded by Piper Sandler with a new price target
- Amendment: SEC Form SCHEDULE 13D/A filed by IO Biotech Inc.
- SEC Form 8-K filed by IO Biotech Inc.
- IO Biotech Announces Exploration of Strategic Alternatives
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates